文献速递乳腺癌放疗

三阴性乳腺癌辅助放疗与帕博利珠单抗同步治疗的耐受性:真实世界经验

Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience.
PubMed 文献 · Adv Radiat Oncol · 2023-10-17

这项双中心双向性研究纳入2021年7月至2023年3月间55例接受新辅助化疗-免疫治疗(帕博利珠单抗)及辅助放疗的早期和局部晚期三阴性乳腺癌患者,比较同步帕博利珠单抗(RT+P组28例)与暂停帕博利珠单抗(RT-only组27例)的放疗耐受性。RT+P组1例3级疼痛,RT-only组1例3级放射性皮炎,两组毒性无差异,放疗期间无心脏或肺部不良事件,中位随访12个月(10-26)无患者复发。

要点

  • 55例三阴性乳腺癌患者中,RT+P组28例与RT-only组27例的放疗毒性无差异。
  • 仅2例发生≥3级毒性:RT+P组1例3级疼痛,RT-only组1例3级放射性皮炎。
  • 放疗期间未报告心脏或肺部不良事件,中位随访12个月(10-26)无患者复发。

核心结论

  • 在这项样本量有限的研究中,作者未发现RT-only组与RT+P组在毒性方面存在差异。
  • 更多研究和更长随访可能增强该证据的强度。

研究设计与样本

  • 双中心双向性研究,纳入2021年7月至2023年3月间接受新辅助化疗-免疫治疗(帕博利珠单抗)及辅助放疗的早期和局部晚期三阴性乳腺癌患者55例。
  • 28例接受辅助放疗同步帕博利珠单抗(RT+P组),27例在辅助放疗期间暂停帕博利珠单抗(RT-only组)。

主要发现

  • RT+P组1例发生3级疼痛,RT-only组1例发生3级放射性皮炎,两组毒性无差异。
  • 放疗期间未报告心脏或肺部不良事件。
  • 中位随访12个月(10-26),无患者复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出该研究样本量有限。
  • 作者指出更多研究和更长随访可能增强该证据的强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiation therapy (RT), and adjuvant pembrolizumab. However, the safety of combining pembrolizumab with adjuvant breast RT has never been evaluated. This study evaluated the tolerance profile of concurrent pembrolizumab with adjuvant RT in patients with locally advanced TNBC. METHODS AND MATERIALS: This bicentric ambispective study included all the patients with early and locally advanced TNBC who received neoadjuvant chemo-immunotherapy with pembrolizumab and adjuvant RT as part of their treatment. The tolerance profile of adjuvant RT was evaluated and compared in patients who received concurrent pembrolizumab and in patients for whom pembrolizumab was withheld. RESULTS: Fifty-five patients were included between July 2021 and March 2023. Twenty-eight patients received adjuvant RT with concurrent pembrolizumab (RT+P group), and 27 patients had pembrolizumab withheld while receiving adjuvant RT (RT-only group). Two patients developed grade ≥3 toxicity (1 grade 3 pain in the RT+P group and 1 grade 3 radiodermatitis in the RT-only group), and there were no differences in terms of toxicity between the RT-only and the RT+P groups. No cardiac or pulmonary adverse event was reported during RT. With a median follow-up of 12 months (10-26), no patient relapsed. CONCLUSIONS: In this study of limited size, the authors did not find a difference between the RT-only and RT+P groups in terms of toxicity. More studies and longer follow-up may add to the strength of this evidence.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Tison T, Loap P, Arnaud E, et al. Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience. Adv Radiat Oncol. 2023. PMID: 38495034. doi:10.1016/j.adro.2023.101384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。